Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth
MWN-AI** Summary
Catheter Precision, Inc. (NYSE American: VTAK) announced a significant improvement to its balance sheet with a strategic financing commitment of up to $88 million aimed at funding its accelerated growth. This financing is particularly timely as it comes on the heels of the acquisition of Fly Flyte, Inc., a subsidiary that enables VTAK to bolster its aviation platform and fuel expansion. The CEO of Flyte, Marc Sellouk, expressed optimism about the fully funded growth strategy, stating it uniquely positions the company to expand fleet operations and enter new markets in response to rising demand for premium regional mobility.
The funding will facilitate crucial initiatives such as fleet expansion, aircraft acquisitions, and market penetration across additional regional corridors. It is also expected to simplify the balance sheet and reduce legacy liabilities, ultimately aiming to create a more streamlined public company with a strong position in the burgeoning regional aviation market.
Flyte is at the forefront of addressing increasing consumer demand for time-efficient regional air mobility, offering premium point-to-point travel services. With a foundation of certified aircraft, active flight operations, and scalable infrastructure, Flyte is poised for expansive growth into high-demand corridors as travelers seek alternatives to congested commercial airports.
Overall, VTAK’s acquisition of Flyte, supported by the newly secured capital, is anticipated to represent a transformational step forward for the Company. The management believes that this strategy aligns with the shift toward private aviation and next-generation transportation infrastructure, tapping into a promising growth opportunity within the regional air mobility sector. As the Company moves ahead, it reflects a commitment to innovation and efficient transportation solutions, setting the stage for future operational success.
MWN-AI** Analysis
Catheter Precision, Inc. (NYSE American: VTAK) has recently secured up to $88 million in strategic institutional financing commitments, marking a significant turning point for the company as it drives forward its growth strategy through its subsidiary, Flyte, Inc. As a financial analyst, several key aspects of this strategic development warrant attention for investors considering engagement with VTAK.
Firstly, the move to fully fund Flyte’s expansion positions VTAK advantageously within the burgeoning regional air mobility sector. As demand for faster and more efficient travel grows, Flyte's technology-enabled operations provide a competitive edge in a relatively untapped market. Investors should note that the acquisition and funding not only streamline VTAK’s operations but also serve to enhance its balance sheet significantly, indicating improved financial health.
Additionally, the introduction of new institutional capital signals strong market confidence in VTAK’s business model and future growth potential. As Flyte focuses on scaling operations and establishing flight routes, VTAK stands to benefit from heightened demand for premium regional air travel. The operational readiness of Flyte, alongside an active and certified fleet, positions the company well to capture this demand effectively.
Yet, potential investors must remain vigilant regarding the risks inherent in the aviation sector, including regulatory challenges and market competition. The forward-looking nature of many company statements underscores the necessity for continued scrutiny of performance against stated objectives.
In conclusion, Catheter Precision's strategic financing and commitment to transform into a streamlined, growth-oriented operation in regional air mobility present a compelling investment opportunity. Assessing both the promising market potential and associated risks will be paramount for investors contemplating positions in VTAK as it embarks on this significant growth phase.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FORT MILL, S.C., March 11, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) today announced transformational balance sheet improvements through new institutional capital commitments supporting the Company’s next phase of growth.
Fully Funded Growth Strategy
Fly Flyte, Inc. (“Flyte”), a newly acquired subsidiary of VTAK, is now positioned to execute its expansion strategy with a fully funded growth plan supported by its parent company, Catheter Precision.
VTAK has recently completed multiple strategic financings designed to support the Company’s transformation and the expansion of the Flyte aviation platform. The financing also provides capital to fund the Company’s medical device operations.
“With a fully funded growth strategy and access to significant institutional capital, we believe Flyte is uniquely positioned to expand fleet operations, enter new markets, and scale nationally,” said Marc Sellouk, Founder and CEO of Flyte. “Demand for premium regional mobility continues to accelerate, and our platform is built to meet that demand today.”
Capital to Accelerate Platform Expansion
The Company’s recent capital initiatives are expected to support the continued expansion of the Flyte platform and the Company’s broader operational transformation.
Capital intended to support:
- Fleet expansion and aircraft acquisitions
- Market expansion across additional regional corridors
- Scaling Flyte’s aviation platform infrastructure
- Balance sheet simplification
- Reduction of legacy liabilities
Management believes these initiatives position the Company as a more streamlined public company with significant exposure to the rapidly expanding regional aviation market.
Building a Scalable National Aviation Platform
Flyte was founded to address the growing demand for time-efficient regional air mobility, offering premium point-to-point travel between major metropolitan regions and underserved secondary markets.
The platform integrates:
- Certified aircraft and active flight operations
- Established route infrastructure across key regional markets
- A scalable fleet expansion strategy
- Technology-enabled logistics and scheduling
Following the recent completion of the acquisition, Catheter Precision owns 100% of Flyte, creating a unified aviation business positioned for national expansion.
Management believes the platform’s operational foundation allows for rapid fleet growth and expansion into additional high-demand regional markets.
Flyte operates a growing fleet of certified aircraft serving high-demand travel corridors and is designed to scale rapidly as travelers increasingly seek faster alternatives to congested commercial airports and inefficient ground transportation routes.
Management believes the acquisition of Flyte, combined with recently secured institutional capital, provides the foundation for a focused, high-growth aviation strategy while also enabling the Company to simplify its balance sheet and streamline legacy operations.
“This transaction represents a transformational step for the Company,” Sellouk added. “By combining a fully operational aviation platform with newly secured growth capital, we are positioned to scale rapidly and execute our vision of building a national regional air mobility network.”
Regional Air Mobility Market Opportunity
Demand for premium regional air travel continues to increase as travelers prioritize time efficiency and direct point-to-point routes.
The regional air mobility sector is widely viewed as a major growth opportunity within the broader aviation industry, driven by evolving travel patterns and increasing demand for faster regional transportation options.
With certified aircraft, active flight operations, and scalable infrastructure, Flyte provides exposure to this emerging sector through a platform that is already operating today.
Management believes this strategy positions Catheter Precision at the intersection of private aviation, regional air mobility, and next-generation transportation infrastructure.
Additional Information
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company’s Current Report on Form 8-K filed March 9, 2026, for additional details regarding the transaction, which is subject to customary closing conditions, including shareholder approval with respect to certain elements of the transaction.
About Flyte
Flyte is a technology-enabled Regional Air Mobility Company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter travel.
Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.
For more information, visit www.flyte.travel
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The company focuses on bringing new technologies to market through collaboration with physicians and continuous product innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “focus,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our belief Flyte is uniquely positioned to expand fleet operations, enter new markets, and scale nationally, our belief our capital initiatives position the Company as a more streamlined public company with significant exposure to the rapidly expanding regional aviation market, the belief that FLYTE’s platform operational foundation allows for rapid fleet growth and expansion into additional high-demand regional markets and our belief the acquisition of Flyte, combined with recently secured institutional capital, provides the foundation for a focused, high-growth aviation strategy while also enabling the Company to simplify its balance sheet and streamline legacy operations. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. Unless otherwise required by law, the Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether because of new information, a future event, or otherwise and such statements are made only as of the date hereof. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K and Form 10-Q’s, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at www.sec.gov.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
###
FAQ**
How does Catheter Precision Inc. VTAK plan to utilize the recently secured institutional capital to ensure the successful expansion of the Flyte aviation platform?
What are the specific high-demand regional markets that Catheter Precision Inc. VTAK intends to target as part of its growth strategy with Flyte?
In what ways will the acquisition of Flyte enhance Catheter Precision Inc. VTAK's overall operations and financial performance in the coming years?
How does Catheter Precision Inc. VTAK plan to mitigate risks associated with its forward-looking statements related to the expansion of its aviation operations?
**MWN-AI FAQ is based on asking OpenAI questions about Catheter Precision Inc. (NYSE: VTAK).
NASDAQ: VTAK
VTAK Trading
-6.43% G/L:
$1.207 Last:
65,796 Volume:
$1.28 Open:
